Edge-to-Edge Repair Reduces Hospitalization and Mortality Rates in Secondary Mitral Valve Regurgitation?

Severe secondary mitral valve regurgitation is associated to hospitalization and mortality. 

¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

The COAPT study has shown the superiority of guideline directed medical therapy at maximal tolerated doses according to guidelines (GDMT) plus edge-to-edge transcatheter repair (TEER) versus GMDT alone.

However, at present there is no information on the impact of hospitalizations and their relationship to all-cause or cardiovascular mortality. 

The COAPT study was analyzed, including 614 patients: 302 receiving GDMT + TEER and 312 GDMT alone. 

This analysis included hospitalization for any cause (ACH), hospitalization for cardiovascular cause (CCH), hospitalization for cardiac failure (CFH), non-cardiovascular related hospitalization (NCCH), and all-cause mortality.

436 patients (71%) had been hospitalized at least once at 2-year followup. 

Read also: BEST-CLI: Revascularization of Critical Lower Limb Ischemia, a Pragmatic Study.

Mean age was 74, 35% were women. There were no differences in diabetes, hypertension, COPD, PCI, CABG, and peripheral vascular disease. Hospitalized patients showed higher rates of kidney failure, atrial fibrillation, STS score, and higher BNP, in addition to worse 6-minute walk test performance and worse quality of life.  The echo-Doppler prior randomization showed more severe tricuspid failure and higher right ventricular systolic pressure. 

There was no difference between patients receiving GMDT + TEER o GMDT alone between randomization and first hospitalization. Mean time was 253 days.

After 2 years, patients receiving GDMT + TEER presented lower ACH, CCH and CFH globally, both fatal and non-fatal, with no difference in NCCH or hospitalization not related to cardiac failure. 

In addition, those receiving the device lived 2 months longer and outside the hospital. 

Read also: Sex Differences According to Thrombus Burden in STEMI Patients.

Mortality was associated to hospitalization, growing significantly as the number of hospitalizations increased. 

At multivariable analysis, GMDT + TEER was associated with significantly lower all-cause and cardiovascular mortality and hospitalization for cardiac failure. 

Conclusion

The COAPT looked at patients with heart failure and severe secondary mitral valve regurgitation receiving GDMT + TEER, presenting at 2 years fewer fatal hospitalizations, fewer hospitalizations for cardiac failure, and longer survival outside the hospital vs. patients receiving GDMT alone. Hospitalization for cardiac failure was strongly associated with mortality, regardless the treatment.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure The COAPT Trial.

Reference: Gennaro Giustino, et al. J Am Coll Cardiol 2022;80:1857–1868.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Impact of Iliofemoral Disease on Post TAVR Clinical Outcomes: HOSTILE Score Validation

At present, transcatheter aortic valve replacement (TAVR) has been shown safe and effective for treating severe symptomatic aortic stenosis in high-surgical-risk patients. Moreover, its...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...